lidocaine + magnesium sulfate

This is an investigational combination therapy of lidocaine and magnesium sulfate evaluated in a Phase 4 randomized, double-blind, placebo-controlled trial conducted by the University of Wisconsin, Madison. The study (ClinicalTrials.gov identifier NCT01342510) was designed to test whether pretreatment with intravenous lidocaine (50 mg) combined with magnesium sulfate (0.25 g) would have an additive effect in reducing propofol injection pain compared to monotherapies or saline placebo. Lidocaine is a local anesthetic that blocks voltage-gated sodium channels, while magnesium sulfate acts as an NMDA receptor antagonist and vasodilator. The trial concluded that the combination did not provide additional benefit over lidocaine alone for reducing propofol injection pain.

Other names

lidocaine/magnesiummagnesium and lidocaine